Insider Selling: Galectin Therapeutics (NASDAQ:GALT) Insider Sells $78,277.90 in Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 21,446 shares of the business’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $3.65, for a total value of $78,277.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Khurram Jamil also recently made the following trade(s):

• On Monday, January 5th, Khurram Jamil sold 25,499 shares of Galectin Therapeutics stock. The stock was sold at an average price of $3.90, for a total value of $99,446.10.
• On Friday, January 2nd, Khurram Jamil sold 13,055 shares of Galectin Therapeutics stock. The shares were sold at an average price of $4.20, for a total value of $54,831.00.
• On Wednesday, December 17th, Khurram Jamil sold 19,442 shares of Galectin Therapeutics stock. The stock was sold at an average price of $7.04, for a total value of $136,871.68.
• On Thursday, November 13th, Khurram Jamil sold 121,117 shares of Galectin Therapeutics stock. The shares were sold at an average price of $5.47, for a total transaction of $662,509.99.

Galectin Therapeutics Stock Performance

Shares of NASDAQ GALT opened at $3.20 on Friday. The company has a market capitalization of $206.30 million, a PE ratio of -5.42 and a beta of 1.03. The company’s fifty day moving average price is $5.24 and its 200 day moving average price is $4.38. Galectin Therapeutics Inc. has a 1 year low of $1.07 and a 1 year high of $7.13.

Galectin Therapeutics (NASDAQ:GALT) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, equities analysts expect that Galectin Therapeutics Inc. will post -0.73 EPS for the current year.

Analysts Set New Price Targets

GALT has been the subject of a number of recent analyst reports. HC Wainwright boosted their price objective on Galectin Therapeutics from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $11.00.

Hedge Funds Weigh In On Galectin Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in GALT. Atwood & Palmer Inc. acquired a new stake in shares of Galectin Therapeutics in the third quarter worth approximately $42,000. Archer Investment Corp acquired a new stake in Galectin Therapeutics during the 3rd quarter worth $47,000. Hudson Bay Capital Management LP purchased a new stake in shares of Galectin Therapeutics during the third quarter worth $63,000. JPMorgan Chase & Co. raised its position in shares of Galectin Therapeutics by 25.4% in the third quarter. JPMorgan Chase & Co. now owns 15,470 shares of the company’s stock valued at $66,000 after buying an additional 3,133 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of Galectin Therapeutics in the third quarter valued at about $70,000. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.